Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia
- PMID: 8243570
Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia
Abstract
The bcr/abl transcript is specifically expressed in the hematopoietic cells of patients with chronic myeloid leukemia (CML). The Haseloff and Gerlach model was used to design a ribozyme targeted to this transcript. When tested against a synthetic substrate covering the translocation sequence, the ribozyme exhibited site specificity and an absolute requirement for divalent metal ions. Cleavage of the normal bcr was also noted but at a reduced efficiency compared to that exhibited for the bcr/abl substrate. Importantly, cleavage of the full-length bcr/abl mRNA was achieved at physiologic temperature, demonstrating effective ribozyme-mediated cleavage.
Similar articles
-
Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.Cancer Gene Ther. 2002 Jan;9(1):71-86. doi: 10.1038/sj.cgt.7700410. Cancer Gene Ther. 2002. PMID: 11916246
-
Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.Exp Hematol. 1995 Aug;23(9):986-9. Exp Hematol. 1995. PMID: 7543419
-
An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.Biochem Biophys Res Commun. 2004 Jun 4;318(3):764-72. doi: 10.1016/j.bbrc.2004.04.088. Biochem Biophys Res Commun. 2004. PMID: 15144904
-
Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.Leuk Lymphoma. 1996 Aug;22(5-6):365-73. doi: 10.3109/10428199609054774. Leuk Lymphoma. 1996. PMID: 8882949 Review.
-
[Target therapy for CML--applying maxizyme].Nihon Rinsho. 2001 Dec;59(12):2439-44. Nihon Rinsho. 2001. PMID: 11766353 Review. Japanese.
Cited by
-
A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.J Cancer Res Clin Oncol. 1997;123(2):91-9. doi: 10.1007/BF01269886. J Cancer Res Clin Oncol. 1997. PMID: 9030247 Free PMC article.
-
Antisense approaches to the gene therapy of cancer--'Recnac'.Cancer Metastasis Rev. 1996 Sep;15(3):287-99. doi: 10.1007/BF00046343. Cancer Metastasis Rev. 1996. PMID: 9034592 Review.
-
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.Nucleic Acids Res. 1997 Aug 1;25(15):3074-81. doi: 10.1093/nar/25.15.3074. Nucleic Acids Res. 1997. PMID: 9224607 Free PMC article.
-
Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.Pharm Res. 1995 Apr;12(4):465-83. doi: 10.1023/a:1016281324761. Pharm Res. 1995. PMID: 7596980 Review.
-
Ribozymes: biology, biochemistry, and implications for clinical medicine.J Mol Med (Berl). 1995 Feb;73(2):65-71. doi: 10.1007/BF00270579. J Mol Med (Berl). 1995. PMID: 7627631 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous